Comparison of gastrointestinal adverse events between fast release tablets and regular acetylsalicylic acid (aspirin) galenics after short-term use: a meta-analysis of randomized clinical trials

Lanas, Angel (Universidad de Zaragoza) ; Werz, Oliver ; Mikhail, Engy

Resumen: This study aimed at determining whether there is a difference in the safety profile between fast release (FR) aspirin tablets and regular galenic formulations of aspirin. This study was based on a clinical study database pool (Bayer HealthCare) including 84 clinical studies and 16,095 human subjects. The meta-analysis included 72 studies applying a single dose of aspirin of at most 1000 mg and was, therefore, based on individual data from 9288 subjects. Of these, 6029 subjects took aspirin and 3259 subjects took placebo. Endpoints were adverse events (AEs) of any kind and, especially of gastrointestinal (GI) nature. Event incidence and odds ratios (OR) based on Mantel–Haenszel risk estimates were calcuated. Subjects on aspirin FR had a significantly decreased OR of 0.65 [0.48, 0.90] [95% confidence interval] for all AEs and of 0.39 [0.20, 0.79] for drug-related all AEs versus placebo. The risk of all GI AEs tended to be reduced for subjects on aspirin FR (0.65 [0.41; 1.03]), but not for drug-related GI AEs. Subject on aspirin mono and aspirin mono (plain only, w/o FR) showed an increased risk of drug-related all AEs compared to placebo (1.34 [1.11; 1.62] and 1.43 [1.13; 1.80]). However, subjects on aspirin FR and those on regular aspirin had almost the same risk of all determined AEs. In conclusion, aspirin FR tablets showed a comparable GI tolerability to regular galenic formulations of aspirin after short-term treatment. Major GI complication did not occur after intake of any galenic formulation of aspirin.

Idioma: Inglés

DOI: 10.1007/s10787-023-01264-3

Año: 2023

Publicado en: INFLAMMOPHARMACOLOGY 31, 5 (2023), 2369-2381
ISSN: 0925-4692

Factor impacto JCR: 4.6 (2023)

Categ. JCR: TOXICOLOGY rank: 17 / 106 = 0.16 (2023) - Q1 - T1
Categ. JCR: IMMUNOLOGY rank: 56 / 181 = 0.309 (2023) - Q2 - T1

Factor impacto CITESCORE: 8.0 - Pharmacology (Q1) - Pharmacology (medical) (Q1) - Immunology (Q2)

Factor impacto SCIMAGO: 0.952 - Pharmacology (Q1) - Pharmacology (medical) (Q1) - Immunology (Q2)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)